Regeneron Pharmaceuticals (REGN) Financial Analysis & Valuation | Quarter Chart

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascular... more
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medic... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$85.88BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOLeonard S. Schleifer
IPO Date1991-04-02CAGR25.54%
Employees15,410Websitewww.regeneron.com
Div. Yield0.12%Payout Ratio9%
Buy Back Yield1.04%Total Yield1.16%
REGN chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$74.26BP/E18.27Forward P/E13.75PEG-4.55
P/S20.47P/B10049811.38P/CF71.74P/FCF90.13
Sales$15.53BSales 1Y9.29%Sales 3Y22.6%Sales 5Y25.44%
EPS$45.63EPS 1Y1.89%EPS 3Y6.87%EPS 5Y-27.4%
Sales QoQ19.01%EPS QoQ80.74%Sales QoQ Avg4.36%EPS QoQ Avg7.66%
Gross Margin83.39%Operating Margin24.74%Profit Margin27.86%ROCE10616298.34%
ROA10372964%ROE18%Altman Z Score5881444.43Piotroski Score7
Current Ratio3.34Quick Ratio2.78Cash Ratio0.44Op. CF Ratio103876.61
Debt/Equity0.06Debt/Assets0.05Lt Debt/Equity0.06Lt Debt/Cap.0.06
Intrst Cov.69.37Inventory Turnover836818.73Asset Turnover372261.6Receivables Turnover2366146.77
Enterprise Value$74.26BP/E Ratio18.27
Forward P/E13.75PEG Ratio-4.55
P/S Ratio20.47P/B Ratio10049811.38
P/CF Ratio71.74P/FCF Ratio90.13
EPS$45.63EPS Growth 1Y1.89%
EPS Growth 3Y6.87%EPS Growth 5Y-27.4%
Revenue Growth 1Y9.29%Gross Margin0.83%
Operating Margin0.25%Profit Margin0.28%
ROE0.18%ROA103729.64%
ROCE106162.98%Current Ratio3.34
Quick Ratio2.78Cash Ratio0.44
Debt/Equity0.06Interest Coverage69.37
Altman Z Score5881444.43Piotroski Score7

View Regeneron Pharmaceuticals financial charts →

Regeneron Pharmaceuticals (REGN) valuation & financials

Regeneron Pharmaceuticals (REGN) has a market capitalization of $85.88B and trades at a price-to-earnings ratio of 18.3. It operates in the Healthcare sector (Biotechnology).

Regeneron Pharmaceuticals's revenue grew +9.3% over the last year.

Regeneron Pharmaceuticals's next earnings report is scheduled for October 28, 2026 before market open; analysts estimate EPS of $16.00. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate REGN EPS of $16.00 for the upcoming quarter. See Regeneron Pharmaceuticals revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Regeneron Pharmaceuticals (REGN) — frequently asked questions

When does Regeneron Pharmaceuticals (REGN) report earnings next?

Regeneron Pharmaceuticals is expected to report earnings on October 28, 2026 before market open. Analysts estimate EPS of $16.00.

What is Regeneron Pharmaceuticals's market cap?

Regeneron Pharmaceuticals (REGN) has a market capitalization of $85.88B.

What is REGN's P/E ratio?

Regeneron Pharmaceuticals trades at a price-to-earnings ratio of 18.3, with trailing twelve-month EPS of $45.63.

How fast is Regeneron Pharmaceuticals growing?

Regeneron Pharmaceuticals's revenue grew +9.3% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)

Regeneron Pharmaceuticals revenue & earnings charts →